In vivo confocal microscopy analysis successful in detecting OSSN characteristics

Article

Using in vivo microscopy analysis is a safe and effective diagnostic tool in detecting ocular surface squamous neoplasia (OSSN) characteristics

Using in vivo microscopy analysis is a safe and effective diagnostic tool in detecting ocular surface squamous neoplasia (OSSN) characteristics, claims a study in the journal Eye.

Dr Y Xu et al., Department of Ophthalmology, Peking University Eye Center, Peking University Third Hospital, Beijing, China, conducted a case series on five patients with OSSN. All characteristics were identified by in vivo confocal microscopy before surgery.

Structure and cellular features of OSSN were analysed with anterior-segment optical coherence tomography (AS-OCT) and confirmed by histopathological biopsy.

The anterior segment photography revealed tumours with red gelatinous surfaces with vascular dilation of the ocular surface and corneal epithelium. In three cases the AS-OCT found only tumours in the corneal epithelium, but the Bowman's layer and anterior stroma were invaded in two of the cases.

In three patients in vivo confocal microscopy revealed cellular anisocystosis and enlarged nuclei with a high nuclear to cytoplasmic ratio. Characteristics identified by histopathological biopsy were similar to the results identified by in vivo confocal microscopy in all patients.

Overall, the procedure is a safe, relatively non-invasive and effective tool in identifying OSSN characteristics. It is a valuable tool for managing OSSN patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.